Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YRYuhong RenLCLuya ChengJXJiadai Xu

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals complete response in 26.9% with glofitamab for aggressive B-cell lymphoma, suggesting viable salvage options.

Key Points

  • Patients demonstrated a median overall survival not reached with glofitamab-based regimens.
  • Among 35 patients treated, the complete response rate was 26.9% and the overall response rate was 50%.
  • Assessment was retrospective, focusing on clinical outcomes in aggressive B-cell lymphoma treatments.
  • Efficacy highlights manageable toxicities, with common adverse events including anemia and cytokine release syndrome.

Cite This Study

Ren et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d740https://doi.org/10.1182/blood-2025-7257
View Full Paper
Ask AI
Bookmark
Share